Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DLL3-SAVVYZ-IL18 CAR-T cells |
| Synonyms | |
| Therapy Description |
Limited information is currently available on DLL3-SAVVYZ-IL18 CAR-T cells, a putative chimeric antigen receptor (CAR) T-cell therapy targeting DLL3 (Aug 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DLL3-SAVVYZ-IL18 CAR-T cells | DLL3-SAVVYZ-IL18 CAR T-cells|DLL3 SAVVYZ IL18 CAR-T cells | Limited information is currently available on DLL3-SAVVYZ-IL18 CAR-T cells, a putative chimeric antigen receptor (CAR) T-cell therapy targeting DLL3 (Aug 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07783477 | Phase I | DLL3-SAVVYZ-IL18 CAR-T cells | A Study of Armored CAR T Cells in People With Cancer | Recruiting | USA | 0 |